Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marlo Brawner

Adolescent Medicine Livingston, TX Medical Doctor

NPI 1033218730 CMS profile 274067

400 Ogletree Dr, Livingston, TX 77351

Open in the dashboard

General payments

$3,925

182 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marlo Brawner of Livingston, TX is reported in the CMS Open Payments database as having received $3,925 across 182 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $642 41
2024 General $879 29
2023 General $473 21
2022 General $751 21
2021 General $664 41
2020 General $371 22
2019 General $146 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marlo Brawner
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to Marlo Brawner were reported at $642. Among 914 Adolescent Medicine profiles paid that year, the median was $100 and the middle half received between $40 and $207.

Show as a table
Year Marlo Brawner Adolescent Medicine median Middle half National median
2019 $146 $95 $36–$198 $163
2020 $371 $50 $23–$111 $114
2021 $664 $67 $27–$179 $132
2022 $751 $79 $29–$189 $149
2023 $473 $100 $39–$194 $160
2024 $879 $93 $38–$195 $164
2025 $642 $100 $40–$207 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ironshore Pharmaceuticals Inc. $967 36 payments
  2. Tris Pharma Inc $892 38 payments
  3. Corium, Inc. $648 42 payments
  4. Supernus Pharmaceuticals, Inc. $609 15 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $168 13 payments
  6. Cranial Technologies, Inc $150 10 payments
  7. Merck Sharp & Dohme Corporation $113 7 payments
  8. Pfizer Inc. $113 6 payments
  9. Sanofi Pasteur Inc. $61 3 payments
  10. GlaxoSmithKline, LLC. $31 2 payments
  11. Other $174 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,925 182 payments
Products named General payments · program years 2019–2025
  1. JORNAY PM Central Nervous Stimulant ADHD $669 27 payments
  2. Azstarys $648 42 payments
  3. Qelbree $492 9 payments
  4. Dyanavel XR Adhd $396 15 payments
  5. Dyanavel XR Adhd $309 10 payments
  6. JORNAY PM Central Nervous System Stimulant $228 7 payments
  7. Quillichew ER $217 2 payments
  8. Quillivant $217 2 payments
  9. VYVANSE $193 15 payments
  10. Doc Band $150 10 payments
  11. Other $1,569 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

182 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record